HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Terremoto wins $108m in Series C to drive cancer and rare disease programmes

Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.

By Pharmaceutical Technology · Apr 16, 2026 · via Pharmaceutical Technology
Terremoto wins $108m in Series C to drive cancer and rare disease programmes

Image: Pharmaceutical Technology

Tags
moneyformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
Odyssey Therapeutics will try again to IPO, this time in a warmer market
MoneyEndpoints News ↗
Odyssey Therapeutics will try again to IPO, this time in a warmer market
A year after pulling its first try at an IPO, Odyssey Therapeutics is giving it another go. On Friday night, t…
Apr 20, 2026
Big Pharma’s M&A Jag Freezes Biotech IPO Window
MoneyBriefing
Big Pharma’s M&A Jag Freezes Biotech IPO Window
Seven pharma takeovers over $1B each in late March, totaling $29B, may have sidelined would‑be biotech IPOs af…
Apr 17, 2026
Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
MoneyFierceBiotech ↗
Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pan…
Apr 17, 2026